Panacea Biotec Q3FY26: Standalone Net Loss ₹7.36 Cr, Consolidated Net Profit ₹3.89 Cr
Panacea Biotec reported standalone net loss of ₹7.36 crore for Q3FY26, widening from ₹15.64 crore loss in Q3FY25. Consolidated net profit stood at ₹3.89 crore for Q3FY26, a turnaround from ₹14.01 crore loss in Q3FY25. Nine-month standalone net loss was ₹29.70 crore, while consolidated net profit was ₹6.16 crore.
The announcement includes financial results, which are material for investors. While the consolidated profit is a positive sign, the standalone loss and the decrease in consolidated profit for the nine-month period indicate a mixed impact.
The standalone results show a widening loss, while the consolidated results show a profit but a decrease in earnings compared to the previous year's nine-month period. This mixed performance leads to a neutral sentiment.
Panacea Biotec Limited announced its standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results in a meeting held on February 11, 2026.
On a standalone basis, the company reported a net loss after tax of ₹7.36 crore for the quarter ended December 31, 2025, compared to a net loss of ₹15.64 crore in the same period last year. For the nine months ended December 31, 2025, the standalone net loss was ₹29.70 crore, a widening from ₹2.84 crore in the corresponding period of the previous year.
Consolidated, the Group reported a net profit after tax of ₹3.89 crore for the quarter ended December 31, 2025, a significant improvement from a net loss of ₹14.01 crore in the same quarter last year. However, for the nine months ended December 31, 2025, the consolidated net profit was ₹6.16 crore, a decrease from ₹8.72 crore in the prior year period. Total consolidated income from operations for the quarter was ₹16,519 lakh (₹165.19 crore), and for the nine months was ₹47,302 lakh (₹473.02 crore).
The company's results are prepared in accordance with Indian Accounting Standards (Ind-AS) and have been subjected to a limited review by the statutory auditors. The financial results are available on the company's website and the stock exchanges.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.